BHC · Bausch Health Companies Inc. · Executive Compensation
$8.22
-0.34 (-3.97%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$3.08B
Shares
374.27M
Volume · Nov 20
3.84M
Avg daily vol (3M)
3.18M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Thomas J. Appio | Chief Executive Officer | $16,877,326 |
| Aimee J. Lenar | Executive Vice President, US Pharma | $3,264,491 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Thomas J. Appio | Chief Executive Officer | $16,239,133 |
| Jean-Jaques Charhon | Executive Vice President and Chief Financial Officer | $4,267,087 |
| Jean-Jacques Charhon | Executive Vice President, Chief Financial Officer | $4,267,087 |
| Seana Carson | Executive Vice President and General Counsel | $3,972,479 |
| Aimee J. Lenar | Executive Vice President, US Pharma | $1,986,437 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Thomas J. Appio | Chief Executive Officer | $15,878,578 |
| Seana Carson | Executive Vice President and General Counsel | $3,157,817 |
| John S. Barresi | Senior Vice President, Controller, Chief Accounting Officer and former interim Chief Financial Officer | $1,403,801 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Thomas J. Appio | Chief Executive Officer | $13,171,461 |
| Tom Vadaketh | Executive Vice President and Chief Financial Officer | $9,011,699 |
| Robert A. Spurr | Former President US Pharmaceutical Business | $4,303,097 |
| Seana Carson | Executive Vice President and General Counsel | $4,212,695 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Joseph C. Papa | Former Chief Executive Officer | $22,889,137 |
| Thomas J. Appio | Chief Executive Officer | $10,188,046 |
| Paul S. Herendeen | Former Executive Vice President and Chief Financial Officer | $6,898,849 |
| Christina M. Ackermann | Former Executive Vice President and General Counsel and Head of Commercial Operations | $4,574,588 |
| Sam Eldessouky | Former Executive Vice President and Chief Financial Officer | $4,332,224 |
| Robert A. Spurr | President, U.S. Pharma Business | $3,868,624 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Joseph C. Papa | Former Chief Executive Officer | $14,119,361 |
| Paul S. Herendeen | Former Executive Vice President and Chief Financial Officer | $5,966,103 |
| Thomas J. Appio | Chief Executive Officer | $3,828,387 |
| William D. Humphries | Former President, | $3,815,433 |
| Christina M. Ackermann | Former Executive Vice President and General Counsel and Head of Commercial Operations | $3,541,028 |
| Sam Eldessouky | Former Executive Vice President and Chief Financial Officer | $1,318,165 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Joseph C. Papa | Chief Executive Officer | $17,141,646 |
| Paul S. Herendeen | Former Executive Vice President and Chief Financial Officer | $6,977,361 |
| Thomas J. Appio | President & Co-Head Bausch + Lomb/International | $3,958,001 |
| William D. Humphries | Former President, | $3,615,591 |
| Christina M. Ackermann | Executive Vice President, General Counsel and Head of Commercial Operations | $3,379,932 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Joseph C. Papa | Chief Executive Officer | $14,741,050 |
| Paul S. Herendeen | Executive Vice President and Chief Financial Officer | $6,400,807 |
| Thomas J. Appio | President & Co-Head Bausch + Lomb/International | $4,386,602 |
| Christina M. Ackermann | Executive Vice President, General Counsel and Head of Commercial Operations | $3,386,907 |
| Ortho Dermatologics | — | $1,374,375 |
| William D. Humphries | President, | $1,374,375 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Ortho Dermatologics | — | $8,434,206 |
| Joseph C. Papa | Chief Executive Officer | $4,895,108 |
| Thomas J. Appio | President & Co-Head Bausch + Lomb/International | $3,429,286 |
| Christina M. Ackermann | Executive Vice President and General Counsel | $2,795,152 |
| Paul S. Herendeen | Executive Vice President and Chief Financial Officer | $2,597,950 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
Michael Goettler
“Mr. Goettler’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2026-07-01 |
|
Steven D. Miller
“The resignations of Messrs. Icahn and Miller did not result from any disagreement with the Company.”
|
board of directors | Resigned | 2025-08-15 |
|
Brett M. Icahn
“The resignations of Messrs. Icahn and Miller did not result from any disagreement with the Company.”
|
board of directors | Resigned | 2025-08-15 |
| Sandra Leung | member of the Board of Directors | Appointed | 2025-07-24 |
| Michael Goettler | member of the Board of Directors | Appointed | 2025-07-24 |
| Steven Lee | Senior Vice President, Controller and Chief Accounting Officer | Appointed | 2025-07-10 |
|
John S. Barresi
“Mr. Barresi’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting principles, practices and disclosures.”
|
Senior Vice President, Controller and Chief Accounting Officer | Resigned | 2025-05-15 |
| Aimee Lenar | Executive Vice President, US Pharma | Appointed | 2024-07-19 |
| Jean-Jacques Charhon | Executive Vice President and Chief Financial Officer | Appointed | 2024-07-19 |
|
Thomas W. Ross, Sr.
“The retirement of each of Mr. Robertson and Mr. Ross was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.”
|
member of the Board | Retired | 2024-02-01 |
|
Russel C. Robertson
“The retirement of each of Mr. Robertson and Mr. Ross was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.”
|
member of the Board | Retired | 2024-02-01 |
|
Tom Vadaketh
“Mr. Vadaketh's resignation was not because of any disagreement with the Company on any matter relating to the Company's operations, policies or practices, including accounting principles, practices and disclosures.”
|
Executive Vice President, Chief Financial Officer | Resigned | 2023-09-18 |
|
Argeris Karabelas
“The retirement of each of Mr. De Schutter and Dr. Karabelas was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.”
|
director | Retired | 2023-03-01 |
|
Richard De Schutter
“The retirement of each of Mr. De Schutter and Dr. Karabelas was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.”
|
director | Retired | 2023-03-01 |
| John A. Paulson | Board | Appointed | 2022-06-24 |
|
Joseph C. Papa
“Mr. Papa’s decision to resign from the Board was not due to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2022-06-24 |
| Amy B. Wechsler, M.D. | Director | Appointed | 2022-06-24 |
| Thomas W. Ross, Sr. | Director | Appointed | 2022-06-24 |
| Russel C. Robertson | Director | Appointed | 2022-06-24 |
| Joseph C. Papa | Director | Appointed | 2022-06-24 |
| Robert N. Power | Director | Appointed | 2022-06-24 |
| Dr. Richard C. Mulligan | Director | Appointed | 2022-06-24 |
| Steven D. Miller | Director | Appointed | 2022-06-24 |
| Dr. Argeris (Jerry) N. Karabelas | Director | Appointed | 2022-06-24 |
| Sarah B. Kavanagh | Director | Appointed | 2022-06-24 |
Leadership
- Joseph Papa CEO
- Thomas Appio CEO
- Thomas J. Appio CEO, Board Member
- John A. Paulson Chairman, Board Member
- Jean-Jacques Charhon CFO
- Jean-Jaques Charhon CFO
- John Barresi CFO
- Paul Herendeen CFO
- Seana Carson General Counsel
- John S. Barresi Chief Accounting Officer
- Steven Lee Chief Accounting Officer
- Amy B. Wechsler, M.D. Board Member
- Brett Icahn Board Member
- Dr. Argeris (Jerry) N. Karabelas Board Member
- Dr. Richard C. Mulligan Board Member
- Michael Goettler Board Member
- Richard C. Mulligan Board Member
- Richard U. De Schutter Board Member
- Robert N. Power Board Member
- Russel C. Robertson Board Member
- Sandra Leung Board Member
- Sarah B. Kavanagh Board Member
- Steven D. Miller Board Member
- Thomas W. Ross, Sr. Board Member
Key facts
CIK
885590
CUSIP
071734107
13F (30d)
235 filings
213 filers
Visit website
Investor relations